We are excited to share an important milestone in our journey at SCHOTT Poonawalla. As one of India’s leading experts in premium parenteral packaging systems made from tubular glass, our company has long been committed to serving the pharmaceutical industry with an extensive product portfolio that includes vials, pre-fillable syringes, ampoules, and cartridges. Established in 1990 as a premium manufacturer of tubular glass pharmaceutical containers, our growth has been driven by continuous innovation and our unwavering commitment to quality. Our 50-50 joint venture partnership with SCHOTT Pharma AG & Co. KGaA—one of the world’s leading experts in glass parenteral packaging, headquartered in Mainz, Germany—has further reinforced our position as a trusted name in the market.
In our recent funding announcement, we would like to clarify that SCHOTT Poonawalla has raised 0 in this particular round. While no external funds were raised at this time, this outcome reflects our robust financial stability and our dedication to reinvesting in our own growth. The decision to refrain from new funding allowed us to strategically opt for internal financing, directing valuable resources toward research and development, technology upgrades, and expanding our manufacturing capacities. This approach not only reinforces our long-term vision but also underscores our commitment to sustainable growth and operational excellence. As we continue to innovate in the premium parenteral packaging segment, we remain focused on enhancing our product portfolio and maintaining the high standards our clients expect, ensuring that we stay at the forefront of advancements in glass packaging solutions for the pharmaceutical industry.
